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Abstract
Background: This paper presents a retrospective statistical study on the newly-released data set
by the Stanley Neuropathology Consortium on gene expression in bipolar disorder and
schizophrenia. This data set contains gene expression data as well as limited demographic and
clinical data for each subject. Previous studies using statistical classification or machine learning
algorithms have focused on gene expression data only. The present paper investigates if such
techniques can benefit from including demographic and clinical data.
Results: We compare six classification algorithms: support vector machines (SVMs), nearest
shrunken centroids, decision trees, ensemble of voters, naïve Bayes, and nearest neighbor. SVMs
outperform the other algorithms. Using expression data only, they yield an area under the ROC
curve of 0.92 for bipolar disorder versus control, and 0.91 for schizophrenia versus control. By
including demographic and clinical data, classification performance improves to 0.97 and 0.94
respectively.
Conclusion:  This paper demonstrates that SVMs can distinguish bipolar disorder and
schizophrenia from normal control at a very high rate. Moreover, it shows that classification
performance improves by including demographic and clinical data. We also found that some
variables in this data set, such as alcohol and drug use, are strongly associated to the diseases. These
variables may affect gene expression and make it more difficult to identify genes that are directly
associated to the diseases. Stratification can correct for such variables, but we show that this
reduces the power of the statistical methods.
Background
The Stanley Neuropathology Consortium [1] recently
made a large (over 300 sample) data set publicly available
on gene expression in the brains of deceased individuals
with bipolar disorder or schizophrenia, as well as con-
trols. In addition the data contains limited demographic
and clinical history information, including gender and
history of smoking, alcohol and drug use. This paper
presents a retrospective statistical study on this data set, in
which we address the following three questions:
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Q1. Can either bipolar disorder or schizophrenia be dis-
tinguished from control purely on the basis of gene
expression profile?
Q2. Does addition of the demographic and clinical his-
tory data further improve the ability to distinguish bipolar
disorder or schizophrenia from control?
Q3. Is there a significant difference between the abilities
of different widely-used data analysis algorithms to make
these distinctions?
We show that bipolar disorder and schizophrenia each
can be distinguished from control, based on gene expres-
sion alone, significantly better than chance – in fact with
areas under the Receiver Operating Characteristic (ROC)
curve (AUC) of 0.91 (schizophrenia vs. control) and 0.92
(bipolar disorder vs. control). While area under the ROC
curve indicates how well one can distinguish across a
range of specificities (with 0.5 being no better than chance
and 1.0 being perfect distinction), it is also worth noting
that for each task, a sensitivity of 0.85 can be achieved
when operating at a specificity of 0.9. Moreover, by taking
demographic information and clinical history into
account (see Table 1), performance improves to an AUC
of 0.94 for schizophrenia vs. control and to an AUC of
0.97 for bipolar disorder vs. control. To our knowledge,
this is the first statistical comparison of the efficacy of
using a combination of gene expression data and clinical
history data against using gene expression data alone.
With regard to question Q3, the paper shows that support
vector machines (SVMs) significantly outperform the
other most widely used algorithms for statistical classifica-
tion and machine learning for these tasks.
Furthermore, we found that some variables in this data
set, such as alcohol and drug use, are strongly associated
to the diseases. Given that these variables may affect gene
expression, they may make it more difficult to identify
genes that are directly associated to the diseases. (We dis-
cuss this point in detail later in the text.) We have investi-
gated if post-stratification can correct for such variables,
but we found that it significantly reduces the predictive
accuracy of the statistical methods.
Data
The expression data set was obtained from the Stanley
Neuropathology Consortium [1]. The records utilized in
this study are a subset of the entire collection of data. The
data set contains 115 schizophrenia patients, 105 patients
with bipolar disorder and 112 controls. For each subject,
it includes annotated gene expression data and demo-
graphic and clinical information. All data was analyzed
un-blinded. Diagnosis and criteria have been described
previously by Torrey and colleagues [2]. As described in
the same report by Torrey and colleagues, the recreational
or prescription status of drugs for each of the donors was
largely unknown, because the researchers relied on post-
mortem urine toxicology screens that are not always con-
ducted.
The expression data was obtained using Affymetrix
Human Genome U133A GeneChip oligonucleotide
arrays containing 22,283 probe sets (Affymetrix, Santa
Clara, CA). Probe level data was summarized using the
GC content adjusted robust multi-array average (RMA)
method [3]. The data set includes the GC-RMA value of
each probe set as a numerical feature.
The data set records, besides expression data, also demo-
graphic and clinical information about the subjects. Table
1 lists the recorded demographic and clinical features with
their distribution in the three classes. For numeric fea-
tures, it lists the mean and standard deviation, and for
nominal features, the class-wise count of each feature
value.
Algorithms
We define two binary classification tasks on the data set:
schizophrenia versus control and bipolar versus control.
For each task, we compare the following six classification
techniques: support vector machines, nearest shrunken
centroids, decision trees, ensemble of voters, naïve Bayes,
and nearest neighbor. We briefly describe each technique.
The section "Methods" lists the software packages that we
use and explains how the parameters of the different algo-
rithms are set.
Support vector machines
Support vector machines (SVMs, [4]) belong to the family
of generalized linear models. We employ linear SVMs,
which exhibit good classification performance on gene
expression data [5]. A linear SVM is essentially an (n-1)-
dimensional hyper-plane that separates the instances of
the two classes in the n-dimensional feature space. Figure
1a illustrates this for the two dimensional case: the hyper-
plane reduces here to a line, which separates the empty
(class 1) and filled (class 2) circles. The hyper-plane max-
imizes the margin with the closest training instances.
These instances are called the "support vectors" because
they fix the position and orientation of the hyper-plane.
Linear SVMs assume that the training data is linearly sep-
arable. If this is not the case, then SVMs rely instead on the
concept of a soft margin [6]. In the evaluation, we use a
soft margin SVM, which minimizes, in addition to the
margin, also the sum of the distances to the training
instances that are incorrectly classified by the hyper-plane
(the di in Figure 1a).BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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Nearest shrunken centroids
Nearest shrunken centroids (NSC, [7]) is a technique
designed for classifying gene expression data. NSC repre-
sents each class by its centroid (mean feature vector) and
classifies new instances by assigning them the class of the
closest centroid. NSC shrinks the class centroids (ci in Fig-
ure 1b) in the direction of the overall data centroid. This
has the effect that components of a class centroid that after
shrinkage are equal to the corresponding components of
the overall centroid become irrelevant to the classification
process. This occurs for the horizontal component of the
class centroids in Figure 1b. As a result, NSC implicitly
performs a kind of feature selection.
Table 1: Demographic and clinical features
Feature Value (encoding) Control Schiz. Bipolar
Age 44 ± 8 43 ± 9 45 ± 10
S e x M a l e  ( 1 ) 8 18 65 3
Female (-1) 31 29 52
PMI 29 ± 13 31 ± 15 38 ± 17
Brain pH 6.6 ± 0.3 6.4 ± 0.3 6.4 ± 0.3
Left brain Frozen (1) 51 57 59
Fixed (-1) 61 58 46
Brain region FrontalBA46 (1) 101 104 94
FrontalBA46/10 (-1) 11 11 11
HSV 1 OD Z-score 0.1 ± 1.0 -0.2 ± 0.9 -0.0 ± 0.8
HSV 2 OD Z-score -0.2 ± 0.5 -0.1 ± 0.7 0.3 ± 1.3
Smoking at TOD Yes (1) 29 71 47
No (-1) 29 19 18
U n k n o w n  ( 0 ) 5 42 54 0
Alcohol use Unknown (1) 0 0 4
L i t t l e  o r  n o n e  ( 2 ) 5 63 51 2
Social (3) 38 22 24
Moderate in past (4) 4 10 16
Moderate in present (5) 8 10 10
Heavy in past (6) 6 11 16
Heavy in present (7) 0 27 23
Drug use Unknown (1) 0 6 0
L i t t l e  o r  n o n e  ( 2 ) 9 75 23 2
Social (3) 7 7 8
Moderate in past (4) 5 13 21
Moderate in present (5) 3 8 12
Heavy in past (6) 0 11 6
Heavy in present (7) 0 18 26
Rate of death Sudden (1) 110 91 96
Possible anoxia (2) 0 18 6
Slow death (3) 2 3 0
Mechanical ventilator (4) 0 3 3
This table lists the distribution (count or mean ± standard deviation) of the demographic features in the three classes (control, schizophrenia, 
bipolar disorder). Because most classification techniques are restricted to numerical features only, we reencode each nominal feature as a numeric 
feature. The numerical encoding is listed between parentheses after each nominal feature value.BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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Decision trees
Decision trees (DTs, [8]) are tree-shaped symbolic models
with tests on the feature values in the internal nodes, and
class labels in the leaves (Figure 1c). DTs classify a new
instance by sorting it down the tree, according to the tests
in the nodes, until it reaches a leaf; the label of the leaf
becomes the predicted class of the new instance. C4.5 [8]
is a well-known algorithm for constructing decision trees.
C4.5 builds a DT top-down, by recursively partitioning
the data at each step by a test comparing a feature to a
value. At each node, the algorithm selects the test that
maximizes a heuristic function called information gain
ratio. The better a test is able to separate the instances of
the two classes, the higher its information gain ratio.
Then, it partitions the training instances based on the
selected test, and finally it recursively repeats the same
procedure to construct a sub-tree for each subset in the
partition. C4.5 creates a leaf if all remaining instances
belong to the same class or if there are fewer instances
than a user defined threshold. The label of the leaf is the
majority class of the instances it covers. After building the
tree, C4.5 prunes back some parts to reduce the expected
error on new instances.
Ensemble of voters
Ensemble of voters (EOV, [9]) is a simple ensemble
method. An EOV model is a set of decision stumps. Deci-
sion stumps are decision trees that consist of precisely one
test node with two leaves. The EOV model includes one
decision stump for each of the top N feature value tests
ranked by the information gain score [8]. To obtain a pre-
diction for a new instance, the model combines the pre-
dictions of the stumps by means of majority voting: the
predicted class is the class predicted by more than N/2
stumps.
Naïve Bayes
Naïve Bayes (NB, [10]) is a statistical classifier based on
Bayes rule. Its name comes from the strong (naïve) statis-
tical independence assumptions that it makes. In spite of
these strong assumptions, it often works remarkably well
in practice. NB predicts a class with the rule:
. It estimates
P(c) and P(featurei = valuei|c) from the training data. Note
that NB assumes nominal features, which means that
numerical features must be discretized prior to running
NB.
Nearest neighbor
k-nearest neighbor (kNN, [11]) classifies a new instance as
the majority class of its k closest training instances in the
feature space. For example, 3NN in Figure 1d assigns the
class "black" to the new instance (indicated with a trian-
gle).
Evaluation
We evaluate the performance of the different classification
techniques by means of Receiver Operating Characteristic
(ROC) curves. ROC analysis allows us to simultaneously
compare classifiers for different misclassification costs
and class distributions [12]. It is based on the notions of
"true positive rate" (TP, also known as sensitivity or recall)
and "false positive rate" (FP, also known as 1.0 – specifi-
city). Given two classes "positive" and "negative", TP rate
is the proportion of correctly predicted positive examples,
and FP rate is the proportion of negative examples that are
incorrectly predicted positive. The vertical axis of a ROC
diagram represents TP rate, and the horizontal axis FP
rate. Each classifier corresponds to a point on this dia-
gram. The closer the point is to the upper-left corner (TP
rate = 1, FP rate = 0), the better the classifier.
Most classifiers provide confidence scores for their predic-
tions. For such classifiers, a ROC curve can be constructed.
We present such a curve for each classifier and report the
corresponding "area under curve" (AUC), which is
defined as the area between the ROC curve and the hori-
zontal axis. To obtain a measure for the predictive per-
formance of the models, we estimate the ROC curves
using a 10-fold cross validation procedure. Details about
this evaluation procedure can be found in the section
class P c P feature value c
c classes
ii
i
==
∈ ∏ argmax ( ) ( )
Illustration of the (a) support vector machines, (b) nearest  shrunken centroids, (c) decision trees, and (d) nearest neigh- bor methods Figure 1
Illustration of the (a) support vector machines, (b) 
nearest shrunken centroids, (c) decision trees, and 
(d) nearest neighbor methods.
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"Methods". We use a t-test to assess if the AUC difference
between two classifiers is significant and report the corre-
sponding p-value.
Results and discussion
Classifier performance
We compare the six classification techniques in the con-
text of two classification tasks: schizophrenia versus con-
trol and bipolar versus control. In a first set of
experiments, the data consist of only the gene expression
features (Figures 2, 3, 4, 5, 6, 7), and in a second batch, the
data include both demographic and clinical features as
well as gene expression (Figures 8, 9, 10, 11, 12, 13).
Figure 2 compares the classification techniques for the
schizophrenia versus control task, using only the gene
expression data. SVM outperforms the other techniques. It
yields a cross validated AUC of 0.91, which is significantly
better than NSC (AUC = 0.71, p = 0.002), DT (AUC =
0.64, p = 0.0001), EOV (AUC = 0.71, p = 0.0001), NB
(AUC = 0.71, p = 0.0004), and 3NN (AUC = 0.70, p =
0.0002). The same holds for the bipolar versus control
task (Figure 5). SVM (AUC = 0.92) outperforms the other
techniques. The second best technique is NSC (AUC =
0.73, p = 0.01).
We also present experiments on data for male subjects
only (Figure 3 and Figure 6) and for female subjects only
(Figure 4 and Figure 7), to assess if the diseases can be bet-
ter predicted if data of only one sex is used. The SVM result
AUC = 0.91 on the combined data of Figure 2 for schizo-
phrenia versus control is, however, not significantly differ-
ent from the result for male subjects (Figure 3, AUC =
0.92, p = 0.9) or that for female subjects (Figure 4, AUC =
0.87, p = 0.4). The same holds for the bipolar versus con-
trol task. We hypothesize that this is because the data sets
with subjects of one sex only are much smaller than the
combined data, so that there is less training data for each
model. Even if classification is easier for such data, this is
offset by the smaller data size.
Figures 8, 9, 10, 11, 12, 13 present a similar set of experi-
ments for the data set that includes demographic and clin-
ical data in addition to the gene expression data. Adding
demographic and clinical information improves classifi-
cation performance. SVM, for example, performs better on
the schizophrenia versus control task with demographic
information (Figure 8, AUC = 0.94) than without such
ROC curves, schizophrenia/control, expression data Figure 2
ROC curves, schizophrenia/control, expression data.
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ROC curves, schizophrenia/control, expression data, male  subjects Figure 3
ROC curves, schizophrenia/control, expression data, 
male subjects.
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ROC curves, schizophrenia/control, expression data, female  subjects Figure 4
ROC curves, schizophrenia/control, expression data, 
female subjects.
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additional information (Figure 2, AUC = 0.91, p = 0.06).
The same holds for the other classification techniques and
for the bipolar versus control task (Figure 11 versus Figure
5).
We again present experiments for male and female sub-
jects separately (Figures 9, 10, 12 and 13), this time with
the demographic and clinical data included. The conclu-
sion from this set of experiments is similar to the previous
conclusion: separating the subjects by sex does not signif-
icantly improve the classification performance for SVMs.
The superior performance of SVMs when compared to the
other classification algorithms can be understood based
on the properties of gene expression data. Gene expres-
sion data is typically characterized by a high dimension
combined with a relatively low number of samples. For
example, the present data set records the expression level
of 22,283 probe sets for a number of samples that is two
orders of magnitude smaller. Many classification algo-
rithms are known to perform poorly on such high dimen-
sional data. SVMs, on the other hand, are well suited to
this setting because their classification performance can
be independent of the dimensionality of the feature set
[13]: their performance rather depends on the margin
with which they separate the samples (Figure 1a). This
explains the good performance of SVMs on high dimen-
ROC curves, bipolar/control, expression data Figure 5
ROC curves, bipolar/control, expression data.
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ROC curves, bipolar/control, expression data, male subjects Figure 6
ROC curves, bipolar/control, expression data, male 
subjects.
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
False positive rate (FP)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
T
r
u
e
p
o
s
i
t
i
v
e
r
a
t
e
(
T
P
)
Bipolar/control, expression only, male (53 / 81)
SVM
NSC
DT
EOV
NB
3NN
AUC = 0.89
AUC = 0.55
AUC = 0.52
AUC = 0.57
AUC = 0.48
AUC = 0.58
ROC curves, bipolar/control, expression data, female sub- jects Figure 7
ROC curves, bipolar/control, expression data, female 
subjects.
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ROC curves, schizophrenia/control, demographic, clinical,  and expression data Figure 8
ROC curves, schizophrenia/control, demographic, 
clinical, and expression data.
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sional data. Additional empirical evidence is that SVMs
are known to perform well on text classification problems
(where each word in the vocabulary represents a dimen-
sion) [13]. Previous studies on gene expression data also
illustrate the good performance of SVMs [5,9].
Note that the above discussion does not imply that SVMs
will always outperform other algorithms on gene expres-
sion data. For example, NSC, which implicitly performs
dimensionality reduction (recall that it shrinks the class
centroids towards the overall data centroid), has also been
shown to work well on gene expression data [7,9]. There-
fore, it is common practice in machine learning to evalu-
ate different classification algorithms on a new data set
and based on this evaluation select the one that works
best. This is also the approach that we follow in this work.
Most relevant features
To asses which features are most relevant to each of the
classification tasks, we apply two techniques: (a) ranking
the features by their p-value, and (b) ranking the features
by their SVM weight. The first technique performs, for
each feature, a two-sided t-test comparing the feature's val-
ues in the two classes. It then ranks the features by their t-
test's p-value. Besides the p-values, we also report q-values
[14]. q-values measure significance in terms of the false
discovery rate. For example, if all features with a q-value ≤
ROC curves, schizophrenia/control, all data, male subjects Figure 9
ROC curves, schizophrenia/control, all data, male 
subjects.
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ROC curves, schizophrenia/control, all data, female subjects Figure 10
ROC curves, schizophrenia/control, all data, female 
subjects.
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ROC curves, bipolar/control, demographic, clinical, and  expression data Figure 11
ROC curves, bipolar/control, demographic, clinical, 
and expression data.
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ROC curves, bipolar/control, all data, male subjects Figure 12
ROC curves, bipolar/control, all data, male subjects.
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5% are called significant, then 5% of these features may be
false discoveries, that is, their mean value in the two
classes may be actually identical. We use the software
QVALUE developed by Storey [15] to compute the q-val-
ues. The second technique ranks the features by the weight
that the SVM classifier assigns to each feature in the linear
equation of its classification hyper-plane. The larger the
absolute value of the SVM weight, the more important the
feature is to the classification task.
The QVALUE software computes, in addition to the q-val-
ues, also an estimate of the proportion π0 of truly null fea-
tures. For each of the schizophrenia versus control tasks it
estimates π0 to be 1.0, that is, no significant features; for
the bipolar versus control tasks, π0 ranges from 0.54 to
0.72. Note that the estimate for schizophrenia versus con-
trol is conservative (an overestimate). QVALUE makes cer-
tain assumptions about the p-value distribution of the
data, which do not hold in this case (cf. Figure 14). It is
interesting that, even though QVALUE estimates that
there are no significant individual features, it is still possi-
ble to build classification models that are highly accurate
on previously unseen data. (Recall that SVM yields a cross-
validated AUC of 0.91 for schizophrenia versus control.)
This is partly because the QVALUE estimate is conserva-
tive. But it also is partly because classification techniques
do not rely on a single feature, but exploit the combined
effect of the set of most relevant features. Therefore,
obtaining an accurate classifier is possible even if there are
no individual significant features.
Table 2 (schizophrenia versus control) and Table 3 (bipo-
lar versus control) rank the features by p-value. The left
panel of each table shows results based on expression data
only; the right panel presents results that include the
demographic and clinical features as well. Each table con-
sists of three parts: the top part contains the rankings for
all subjects combined, the middle part the male subjects'
rankings, and the bottom part the female subjects' rank-
ings.(see additional file 3)
Comparing (a) the rankings for expression data only (the
left panels of the tables) to (b) the rankings for expression
and demographic data (the right panels) shows that simi-
lar features appear in (a) and (b). For example, all probe
sets that appear in (b) also appear in (a) for Table 2, all
subjects. In addition, (b) also includes a number of highly
ranked demographic and clinical features. Table 2 shows,
for example, that drug use and alcohol use are ranked high
for the all and male subjects cases. This indicates that
some of the demographic and clinical features are impor-
tant to the classification tasks. Note that we also observed
this while comparing classification models: the models
with demographic and clinical features are more accurate.
When comparing the features that appear in the different
tables, we observe that for the schizophrenia versus con-
trol task (Table 2, expression data), the rankings for all
subjects and male subjects have 14 features in common:
LBH [GenBank:NM_030915], MT1X [Gen-
Bank:NM_002450], MT1X [GenBank:NM_005952],
TNFSF10 [GenBank:NM_003810], ABCG2 [Gen-
Bank:AF098951], MT1E [GenBank:BF217861], SST [Gen-
Bank:NM_001048], CRHBP [GenBank:NM_001882],
EMX2 [GenBank:AI478455], NPY [Gen-
Bank:NM_000905], MT2A [GenBank:NM_005953],
ROC curves, bipolar/control, all data, female subjects Figure 13
ROC curves, bipolar/control, all data, female sub-
jects.
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p-value histogram for (a) schizophrenia/control and (b) bipo- lar/control (expression data, all subjects) Figure 14
p-value histogram for (a) schizophrenia/control and 
(b) bipolar/control (expression data, all subjects). p-
values of truly null features are distributed uniformly, while 
p-values of significant features are clustered around 0.0. This 
translates to a flat histogram with a peak at 0.0, as in (b). The 
p-values in (a) are biased towards 1.0 causing the q-value esti-
mates to be conservative. The reason for observing such 
biased distributions is currently not very well understood 
[59].
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Table 2: Genes sorted by p-value, schizophrenia versus control
Expression data only Demographic, clinical, and expression data
All subjects All subjects
p-value q-value ID GenBank Symbol p-value q-value ID GenBank Symbol
3.92E-08 8.74E-04 221011_s_at NM_030915 LBH 1.39E-10 3.11E-06 Drug use
1.02E-07 1.13E-03 204326_x_at NM_002450 MT1X 2.88E-09 3.21E-05 Alcohol use
2.47E-07 1.84E-03 208581_x_at NM_005952 MT1X 3.92E-08 2.92E-04 221011_s_at NM_030915 LBH
6.37E-07 3.55E-03 202688_at NM_003810 TNFSF10 1.02E-07 5.67E-04 204326_x_at NM_002450 MT1X
1.73E-06 6.20E-03 209735_at AF098951 ABCG2 2.47E-07 1.10E-03 208581_x_at NM_005952 MT1X
1.91E-06 6.20E-03 212859_x_at BF217861 MT1E 6.37E-07 2.37E-03 202688_at NM_003810 TNFSF10
1.95E-06 6.20E-03 205208_at NM_012190 ALDH1L1 1.73E-06 4.83E-03 209735_at AF098951 ABCG2
2.77E-06 7.73E-03 209959_at U12767 NR4A3 1.91E-06 4.83E-03 212859_x_at BF217861 MT1E
3.25E-06 8.04E-03 213921_at NM_001048 SST 1.95E-06 4.83E-03 205208_at NM_012190 ALDH1L1
6.39E-06 1.37E-02 207547_s_at NM_007177 FAM107A 2.77E-06 6.19E-03 209959_at U12767 NR4A3
6.96E-06 1.37E-02 205984_at NM_001882 CRHBP 3.25E-06 6.59E-03 213921_at NM_001048 SST
7.36E-06 1.37E-02 221950_at AI478455 EMX2 6.39E-06 1.13E-02 207547_s_at NM_007177 FAM107A
9.28E-06 1.59E-02 206001_at NM_000905 NPY 6.96E-06 1.13E-02 205984_at NM_001882 CRHBP
1.02E-05 1.63E-02 212185_x_at NM_005953 MT2A 7.36E-06 1.13E-02 221950_at AI478455 EMX2
1.61E-05 2.39E-02 209047_at AL518391 AQP1 7.62E-06 1.13E-02 Smoking at TOD
1.75E-05 2.44E-02 206461_x_at NM_005951 MT1H/P2 9.28E-06 1.29E-02 206001_at NM_000905 NPY
2.06E-05 2.69E-02 202936_s_at NM_000346 SOX9 1.02E-05 1.34E-02 212185_x_at NM_005953 MT2A
2.96E-05 3.50E-02 202917_s_at NM_002964 S100A8 1.61E-05 1.99E-02 209047_at AL518391 AQP1
2.98E-05 3.50E-02 213791_at NM_006211 PENK 1.75E-05 2.06E-02 206461_x_at NM_005951 MT1H/P2
3.43E-05 3.82E-02 205630_at NM_000756 CRH 2.06E-05 2.29E-02 202936_s_at NM_000346 SOX9
Male subjects Male subjects
1.21E-09 2.69E-05 206001_at NM_000905 NPY 2.42E-10 5.40E-06 Drug use
1.18E-08 1.31E-04 205984_at NM_001882 CRHBP 1.21E-09 1.33E-05 206001_at NM_000905 NPY
4.06E-08 3.01E-04 213921_at NM_001048 SST 1.79E-09 1.33E-05 Alcohol use
1.47E-07 8.22E-04 204326_x_at NM_002450 MT1X 1.18E-08 6.56E-05 205984_at NM_001882 CRHBP
1.98E-07 8.81E-04 221011_s_at NM_030915 LBH 2.39E-08 1.06E-04 Brain pH
3.41E-07 1.26E-03 208581_x_at NM_005952 MT1X 4.06E-08 1.51E-04 213921_at NM_001048 SST
8.38E-07 2.67E-03 217911_s_at NM_004281 BAG3 1.47E-07 4.70E-04 204326_x_at NM_002450 MT1X
1.11E-06 3.10E-03 202688_at NM_003810 TNFSF10 1.98E-07 5.51E-04 221011_s_at NM_030915 LBH
3.01E-06 7.27E-03 205336_at NM_002854 PVALB 3.41E-07 8.44E-04 208581_x_at NM_005952 MT1X
3.26E-06 7.27E-03 212859_x_at BF217861 MT1E 8.38E-07 1.87E-03 217911_s_at NM_004281 BAG3
3.72E-06 7.54E-03 209735_at AF098951 ABCG2 1.11E-06 2.26E-03 202688_at NM_003810 TNFSF10
4.18E-06 7.76E-03 220045_at NM_022728 NEUROD6 3.01E-06 5.59E-03 205336_at NM_002854 PVALB
5.00E-06 8.00E-03 221950_at AI478455 EMX2 3.26E-06 5.59E-03 212859_x_at BF217861 MT1E
5.03E-06 8.00E-03 202936_s_at NM_000346 SOX9 3.72E-06 5.93E-03 209735_at AF098951 ABCG2
5.41E-06 8.04E-03 211725_s_at BC005884 BID 4.18E-06 6.21E-03 220045_at NM_022728 NEUROD6
6.56E-06 8.98E-03 202071_at NM_002999 SDC4 5.00E-06 6.59E-03 221950_at AI478455 EMX2
6.85E-06 8.98E-03 212185_x_at NM_005953 MT2A 5.03E-06 6.59E-03 202936_s_at NM_000346 SOX9
8.18E-06 1.01E-02 202917_s_at NM_002964 S100A8 5.41E-06 6.70E-03 211725_s_at BC005884 BID
1.04E-05 1.22E-02 206461_x_at NM_005951 MT1H/P2 6.56E-06 7.63E-03 202071_at NM_002999 SDC4
1.27E-05 1.34E-02 206670_s_at NM_013445 GAD1 6.85E-06 7.63E-03 212185_x_at NM_005953 MT2A
Female subjects Female subjects
4.72E-04 1.00E+00 201041_s_at NM_004417 DUSP1 4.72E-04 1.00E+00 201041_s_at NM_004417 DUSP1
8.02E-04 1.00E+00 208078_s_at NM_030751 SNF1LK 5.93E-04 1.00E+00 Age
1.04E-03 1.00E+00 221841_s_at BF514079 KLF4 8.02E-04 1.00E+00 208078_s_at NM_030751 SNF1LK
1.35E-03 1.00E+00 201865_x_at AI432196 NR3C1 1.04E-03 1.00E+00 221841_s_at BF514079 KLF4
1.85E-03 1.00E+00 219044_at NM_018271 THNSL2 1.35E-03 1.00E+00 201865_x_at AI432196 NR3C1
2.53E-03 1.00E+00 202393_s_at NM_005655 KLF10 1.85E-03 1.00E+00 219044_at NM_018271 THNSL2
3.16E-03 1.00E+00 209189_at BC004490 FOS 2.53E-03 1.00E+00 202393_s_at NM_005655 KLF10
4.09E-03 1.00E+00 201417_at AL136179 SOX4 2.81E-03 1.00E+00 Smoking at TODBMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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MT1H/P2 [GenBank:NM_005951], SOX9 [Gen-
Bank:NM_000346], S100A8 [GenBank:NM_002964].
On the other hand, the rankings for all subjects and
female subjects have only one feature (FAM107A [Gen-
Bank:NM_007177]) in common. For the bipolar versus
control task (Table 3, expression data) all subjects and
male subjects share 6 features (SST [Gen-
Bank:NM_001048], TNFSF10 [GenBank:NM_003810],
NEUROD6 [GenBank:NM_022728], CD74 [Gen-
Bank:K01144], NPY [GenBank:NM_000905], TYROBP
[GenBank:NM_003332]), and all subjects and female
subjects also share 6 features (PPID [Gen-
Bank:NM_005038], WTAP [GenBank:BC000383], RND3
[GenBank:BG054844], DNAJA1 [GenBank:NM_001539],
KIF2A [GenBank:NM_004520]). For both diseases, there
is no overlap between the ranking for the female subjects
and that for the male subjects. Possibly of higher interest
are the features relevant to both the schizophrenia versus
control and bipolar versus control tasks. Comparing the
rankings (the top left rankings of Table 2 and Table 3)
shows that there are 4 common features: LBH [Gen-
Bank:NM_030915], TNFSF10 [GenBank:NM_003810],
SST [GenBank:NM_001048], and NPY [Gen-
Bank:NM_000905]. These are relevant to both diseases.
Table 4 and Table 5 show rankings based on SVM weights.
Also here the relevant features observed for expression
and demographic data are similar to those found for
expression data only. There is also overlap between the
rankings for the different subject subsets (all, male only,
and female only). Note, however, that the features identi-
fied with the SVM weights are different from those identi-
fied with the p-value method. Consider the expression
data only, all subjects rankings. For schizophrenia versus
control, there are no common features in the rankings
produced by the p-value method (Table 2) and the SVM
method (Table 4). For bipolar versus control (Tables 3
and 5), there are two shared features: SST [Gen-
Bank:NM_001048] and LBH [GenBank:NM_030915].
This difference in rankings arises because the methods
essentially have a different goal: the p-value method looks
for individual features that distinguish the two classes
while the SVM method yields a set of features that
together distinguish the classes.
Biological relevance
Of the top 20 genes identified using the p-value ranking,
11 have been previously implicated in schizophrenia in at
least one study. These genes include: NR4A3 [Gen-
Bank:U12767] [16-19], SST [GenBank:NM_001048] [20],
NPY [GenBank:NM_000905] [21,22], S100A8 [Gen-
Bank:NM_002964] [23], CRH [GenBank:NM_000756]
[24,25], GAD1 [GenBank:NM_013445] [26,27], FOS
[GenBank:BC004490] [28,29], JUN [Gen-
Bank:BG491844] [28,29], DNAJB1 [Gen-
Bank:BG537255] [30], SLC16A1 [GenBank:AL162079,
GenBank:BF511091] [31], and EGR2 [Gen-
Bank:NM_000399] [32,17].
Overlap with the current literature occurs for bipolar dis-
order as well, although overlap is not as large primarily
because of the relative immaturity of the field and con-
comitant smaller number of literature results. Of the top
20 genes identified using SVM weight or p-value, 7 genes
have been implicated previously in bipolar disorder.
Interestingly, multiple probes for the same gene are in the
top 20 for DUSP6 [GenBank:BC003143, Gen-
Bank:BC005047] [33,34] and HLA-DRA [Gen-
Bank:M60333, GenBank:M60334] [18]. Single probes
previously implicated in bipolar disorder include: SST
[GenBank:NM_001048] [20], HLA-A [Gen-
Bank:AA573862] [35], NPY [GenBank:NM_000905] [36],
HLA-DRB3 [Genbank:NM_002125] [37], and DNAJB1
[GenBank:BG537255] [30].
Interestingly, most of the remaining genes in the list are
known to interact with the genes that have a documented
association with either bipolar disorder or schizophrenia.
These interactions were determined using Ingenuity Sys-
tems software. 14 of the 20 genes in the schizophrenia
sample are involved in the same biological pathway (Fig-
ure 15). By combining the two networks generated by the
software package via 3 overlapping genes, 19 of the 20
6.61E-03 1.00E+00 211671_s_at U01351 NR3C1 3.16E-03 1.00E+00 209189_at BC004490 FOS
7.38E-03 1.00E+00 209457_at U16996 DUSP5 4.09E-03 1.00E+00 201417_at AL136179 SOX4
9.32E-03 1.00E+00 205856_at NM_015865 SLC14A1 6.61E-03 1.00E+00 211671_s_at U01351 NR3C1
9.73E-03 1.00E+00 213164_at AI867198 SLC5A3 7.38E-03 1.00E+00 209457_at U16996 DUSP5
1.24E-02 1.00E+00 214686_at AA868898 ZNF266 9.32E-03 1.00E+00 205856_at NM_015865 SLC14A1
1.26E-02 1.00E+00 201464_x_at BG491844 JUN 9.73E-03 1.00E+00 213164_at AI867198 SLC5A3
1.26E-02 1.00E+00 209900_s_at AL162079 SLC16A1 1.24E-02 1.00E+00 214686_at AA868898 ZNF266
1.28E-02 1.00E+00 205249_at NM_000399 EGR2 1.26E-02 1.00E+00 201464_x_at BG491844 JUN
1.39E-02 1.00E+00 200664_s_at BG537255 DNAJB1 1.26E-02 1.00E+00 209900_s_at AL162079 SLC16A1
1.62E-02 1.00E+00 202234_s_at BF511091 SLC16A1 1.28E-02 1.00E+00 205249_at NM_000399 EGR2
1.65E-02 1.00E+00 207547_s_at NM_007177 FAM107A 1.39E-02 1.00E+00 200664_s_at BG537255 DNAJB1
1.71E-02 1.00E+00 208691_at BC001188 TFRC 1.62E-02 1.00E+00 202234_s_at BF511091 SLC16A1
Table 2: Genes sorted by p-value, schizophrenia versus control (Continued)BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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Table 3: Genes sorted by p-value, bipolar versus control
Expression data only Demographic, clinical, and expression data
All subjects All subjects
p-value q-value ID GenBank Symbol p-value q-value ID GenBank Symbol
1.37E-09 2.19E-05 213921_at NM_001048 SST 2.92E-18 4.66E-14 Drug use
1.13E-06 5.75E-03 202688_at NM_003810 TNFSF10 7.09E-13 5.66E-09 Alcohol use
1.39E-06 5.75E-03 204185_x_at NM_005038 PPID 1.37E-09 7.31E-06 213921_at NM_001048 SST
1.44E-06 5.75E-03 208290_s_at NM_001969 EIF5 1.13E-06 3.83E-03 202688_at NM_003810 TNFSF10
2.48E-06 7.93E-03 210285_x_at BC000383 WTAP 1.39E-06 3.83E-03 204185_x_at NM_005038 PPID
3.16E-06 8.42E-03 220045_at NM_022728 NEUROD6 1.44E-06 3.83E-03 208290_s_at NM_001969 EIF5
3.88E-06 8.68E-03 211725_s_at BC005884 BID 2.48E-06 5.67E-03 210285_x_at BC000383 WTAP
4.35E-06 8.68E-03 208687_x_at AF352832 HSPA8 3.16E-06 6.32E-03 220045_at NM_022728 NEUROD6
5.27E-06 9.04E-03 212724_at BG054844 RND3 3.88E-06 6.88E-03 211725_s_at BC005884 BID
5.94E-06 9.04E-03 200881_s_at NM_001539 DNAJA1 4.35E-06 6.94E-03 208687_x_at AF352832 HSPA8
6.72E-06 9.04E-03 221011_s_at NM_030915 LBH 5.27E-06 7.66E-03 212724_at BG054844 RND3
6.89E-06 9.04E-03 203087_s_at NM_004520 KIF2A 5.94E-06 7.84E-03 200881_s_at NM_001539 DNAJA1
7.36E-06 9.04E-03 208708_x_at AL080102 EIF5 6.72E-06 7.84E-03 221011_s_at NM_030915 LBH
8.63E-06 9.85E-03 209619_at K01144 CD74 6.89E-06 7.84E-03 203087_s_at NM_004520 KIF2A
9.92E-06 1.01E-02 217932_at NM_015971 MRPS7 7.36E-06 7.84E-03 208708_x_at AL080102 EIF5
1.01E-05 1.01E-02 206001_at NM_000905 NPY 8.63E-06 8.62E-03 209619_at K01144 CD74
1.09E-05 1.01E-02 213038_at AL031602 RNF19B 9.92E-06 9.00E-03 217932_at NM_015971 MRPS7
1.15E-05 1.01E-02 204122_at NM_003332 TYROBP 1.01E-05 9.00E-03 206001_at NM_000905 NPY
1.20E-05 1.01E-02 212861_at BF690150 MFSD5 1.09E-05 9.11E-03 213038_at AL031602 RNF19B
1.47E-05 1.17E-02 211990_at M27487 HLA-DPA1 1.15E-05 9.11E-03 204122_at NM_003332 TYROBP
Male subjects Male subjects
5.38E-07 7.90E-03 202688_at NM_003810 TNFSF10 1.68E-12 2.47E-08 Drug use
1.14E-05 8.36E-02 210982_s_at M60333 HLA-DRA 4.55E-10 3.34E-06 Alcohol use
2.96E-05 1.08E-01 219525_at NM_018242 SLC47A1 5.38E-07 2.63E-03 202688_at NM_003810 TNFSF10
3.21E-05 1.08E-01 205859_at NM_004271 LY86 1.14E-05 4.18E-02 210982_s_at M60333 HLA-DRA
3.66E-05 1.08E-01 208894_at M60334 HLA-DRA 2.96E-05 7.68E-02 219525_at NM_018242 SLC47A1
6.47E-05 1.34E-01 204239_s_at NM_005386 NNAT 3.21E-05 7.68E-02 205859_at NM_004271 LY86
7.61E-05 1.34E-01 220045_at NM_022728 NEUROD6 3.66E-05 7.68E-02 208894_at M60334 HLA-DRA
8.23E-05 1.34E-01 213921_at NM_001048 SST 6.47E-05 1.10E-01 204239_s_at NM_005386 NNAT
8.23E-05 1.34E-01 201720_s_at AI589086 LAPTM5 7.61E-05 1.10E-01 220045_at NM_022728 NEUROD6
1.12E-04 1.65E-01 205984_at NM_001882 CRHBP 8.23E-05 1.10E-01 213921_at NM_001048 SST
1.37E-04 1.82E-01 204174_at NM_001629 ALOX5AP 8.23E-05 1.10E-01 201720_s_at AI589086 LAPTM5
1.57E-04 1.82E-01 209619_at K01144 CD74 1.12E-04 1.38E-01 205984_at NM_001882 CRHBP
1.61E-04 1.82E-01 204981_at NM_002555 SLC22A18 1.37E-04 1.55E-01 204174_at NM_001629 ALOX5AP
1.83E-04 1.92E-01 205404_at NM_005525 HSD11B1 1.57E-04 1.58E-01 209619_at K01144 CD74
1.99E-04 1.95E-01 204122_at NM_003332 TYROBP 1.61E-04 1.58E-01 204981_at NM_002555 SLC22A18
2.84E-04 2.61E-01 211991_s_at M27487 HLA-DPA1 1.83E-04 1.68E-01 205404_at NM_005525 HSD11B1
3.06E-04 2.65E-01 204670_x_at NM_002125 HLA-DRB1 1.99E-04 1.68E-01 204122_at NM_003332 TYROBP
4.02E-04 3.23E-01 220052_s_at NM_012461 TINF2 2.06E-04 1.68E-01 Brain pH
4.18E-04 3.23E-01 206001_at NM_000905 NPY 2.84E-04 2.20E-01 211991_s_at M27487 HLA-DPA1
4.56E-04 3.26E-01 207238_s_at NM_002838 PTPRC 3.06E-04 2.25E-01 204670_x_at NM_002125 HLA-DRB1
Female subjects Female subjects
4.27E-05 3.21E-01 221911_at BE881590 ETV1 3.19E-08 3.84E-04 Drug use
1.55E-04 3.21E-01 217828_at NM_024755 SLTM 6.64E-06 4.00E-02 Age
1.55E-04 3.21E-01 200881_s_at NM_001539 DNAJA1 4.27E-05 1.71E-01 221911_at BE881590 ETV1
1.72E-04 3.21E-01 201170_s_at NM_003670 BHLHB2 1.55E-04 3.00E-01 217828_at NM_024755 SLTM
1.74E-04 3.21E-01 217741_s_at AW471220 ZFAND5 1.55E-04 3.00E-01 200881_s_at NM_001539 DNAJA1
2.52E-04 3.21E-01 212724_at BG054844 RND3 1.72E-04 3.00E-01 201170_s_at NM_003670 BHLHB2
2.54E-04 3.21E-01 212514_x_at R60068 DDX3X 1.74E-04 3.00E-01 217741_s_at AW471220 ZFAND5
3.26E-04 3.21E-01 206302_s_at NM_019094 NUDT4(P1) 2.52E-04 3.21E-01 212724_at BG054844 RND3BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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genes are in a single biological network. Similarly, 13 of
the 20 genes are in a single pathway for bipolar disorder
(Figure 16). By combining two of the 3 generated path-
ways through 3 overlapping genes, this biological network
represents 16 of the 20 genes on the list.
One of the more remarkable features of this analysis is the
difference in gene expression patterns between males and
females. Much speculation has surrounded the role of
gender in psychiatric disorders based on morphological
and clinical comparisons between affected males and
affected females. This analysis may provide further evi-
dence to support and broaden this hypothesis. The most
prevalent gender-based differences associated with mental
disorders are in the structural abnormalities that have
long been known in schizophrenia [38]. These have been
validated using CT and MRI scans, demonstrating differ-
ences in ventricle size in males and females with schizo-
phrenia; specifically the left ventricles of males are known
to be enlarged relative to both their healthy counterparts
and affected females [39-45]. Another structure showing a
difference in affected males and females is the corpus calo-
sum [46-48]. The temporal lobe appears smaller in
affected men than women [49]. Specifically, the superior
temporal gyri [50], the posterior superior temporal gyrus
[51], and Herschel's gyri [51] have all been shown in one
or more studies to be reduced in affected males when
compared to their unaffected male counterparts or
affected females. Volume reductions have also been
observed in the amygdale-hipocampal complex [52].
Reduced asymmetry of the planum temporale has been
observed in females in both MRI and post mortem studies
[53-56]. In this study we provide additional evidence to
further bolster the claim of gender differences, but this
new evidence is in the form of molecular differences
between affected males and females in both schizophre-
nia and bipolar disorder. This may all provide evidence
that gender may have confounded the results of past
molecular analyses into these disorders.
The ranking based on the SVM weights does not produce
a significant number of genes previously implicated in
schizophrenia or bipolar disorder. This does not necessar-
ily mean this measure does not provide as much biologi-
cal insight as the ranking based on p-value. The smaller
overlap may instead be because the SVM-based method is
more different from previous studies than is the method
based on p-values. Whereas previous studies sought indi-
vidual genes, much as the ranking by p-value does, the
ranking by SVM weight seeks genes that are predictive in
the context of other genes. Therefore it seems likely that
this more global look at bipolar disorder and schizophre-
nia is producing genes missed in previous analyses of
microarray data on brain tissue.
Impact of alcohol and drug use
Consider the schizophrenia versus control classification
task. Feature rankings by p-value, such as Table 2, may
include alcohol use (AU) and drug use (DU) associated
genes, and some of these may not be associated to schizo-
phrenia. AU and DU are known to alter gene expression,
that is, there are genes that are differently expressed in
heavy AU/DU subjects and in low AU/DU subjects. Such
AU/DU associated genes will also be differently expressed
in the schizophrenia and control classes, simply because
there are more high AU/DU subjects in the schizophrenia
class, and more low AU/DU subjects in the control class
(Table 1). Therefore, AU/DU associated genes may appear
in the feature rankings (Table 2).
Identical reasoning applies to the bipolar disorder versus
control task, which exhibits a similar difference in AU/DU
distribution between the two classes. This should be kept
in mind when analyzing the rankings. Note that these dif-
ferences in distribution are already present in the popula-
tion and therefore difficult to avoid in the samples.
Post-stratification can potentially be used to remove the
confounding effects of variables such as AU and DU.
Essentially, post-stratification computes a subset of the
data such that the subset's AU/DU distribution is identical
in each class. We have applied post-stratification. A
detailed description of the method that we used together
with its results is available in additional files 1 and 2. In
3.34E-04 3.21E-01 208891_at BC003143 DUSP6 2.54E-04 3.21E-01 212514_x_at R60068 DDX3X
4.26E-04 3.21E-01 208687_x_at AF352832 HSPA8 3.09E-04 3.21E-01 Left brain
4.28E-04 3.21E-01 203087_s_at NM_004520 KIF2A 3.26E-04 3.21E-01 206302_s_at NM_019094 NUDT4(P1)
5.96E-04 3.21E-01 208893_s_at BC005047 DUSP6 3.34E-04 3.21E-01 208891_at BC003143 DUSP6
6.16E-04 3.21E-01 210285_x_at BC000383 WTAP 4.26E-04 3.21E-01 208687_x_at AF352832 HSPA8
6.22E-04 3.21E-01 208852_s_at AI761759 CANX 4.28E-04 3.21E-01 203087_s_at NM_004520 KIF2A
6.78E-04 3.21E-01 208892_s_at BC003143 DUSP6 5.96E-04 3.21E-01 208893_s_at BC005047 DUSP6
6.82E-04 3.21E-01 205251_at NM_022817 PER2 6.16E-04 3.21E-01 210285_x_at BC000383 WTAP
7.09E-04 3.21E-01 200033_at NM_004396 DDX5 6.22E-04 3.21E-01 208852_s_at AI761759 CANX
7.33E-04 3.21E-01 201604_s_at NM_002480 PPP1R12A 6.78E-04 3.21E-01 208892_s_at BC003143 DUSP6
7.45E-04 3.21E-01 204185_x_at NM_005038 PPID 6.82E-04 3.21E-01 205251_at NM_022817 PER2
7.52E-04 3.21E-01 204547_at NM_006822 RAB40B 7.09E-04 3.21E-01 200033_at NM_004396 DDX5
Table 3: Genes sorted by p-value, bipolar versus control (Continued)B
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Table 4: Genes sorted by SVM weight, schizophrenia versus control
Expression data only Demographic, clinical, and expression data
All subjects All subjects
SVM-weight p-value q-value ID GenBank Symbol SVM-weight p-value q-value ID GenBank Symbol
-6.70E-02 1.13E-03 2.46E-01 201137_s_at NM_002121 HLA-DPB1 1.06E-01 1.39E-10 3.11E-06 Drug use
5.99E-02 4.71E-02 1.00E+00 214877_at BE794663 CDKAL1 6.74E-02 2.88E-09 3.21E-05 Alcohol use
-5.62E-02 1.19E-01 1.00E+00 218948_at AL136679 QRSL1 5.16E-02 4.71E-02 1.00E+00 214877_at BE794663 CDKAL1
-5.50E-02 5.31E-05 4.79E-02 203851_at NM_002178 IGFBP6 -5.07E-02 5.31E-05 4.30E-02 203851_at NM_002178 IGFBP6
-5.29E-02 6.22E-03 5.62E-01 204545_at NM_000287 PEX6 -5.05E-02 6.22E-03 5.51E-01 204545_at NM_000287 PEX6
5.21E-02 1.17E-01 1.00E+00 202944_at NM_000262 NAGA -4.84E-02 1.19E-01 1.00E+00 218948_at AL136679 QRSL1
-4.83E-02 7.19E-02 1.00E+00 201123_s_at NM_001970 EIF5A 4.60E-02 1.17E-01 1.00E+00 202944_at NM_000262 NAGA
4.79E-02 7.06E-02 1.00E+00 210075_at AF151074 2-Mar 4.57E-02 9.84E-02 1.00E+00 206785_s_at NM_002260 KLRC2/1
4.76E-02 7.70E-02 1.00E+00 204418_x_at NM_000848 GSTM2 -4.56E-02 1.13E-03 2.35E-01 201137_s_at NM_002121 HLA-DPB1
4.76E-02 6.82E-02 1.00E+00 204550_x_at NM_000561 GSTM1 -4.55E-02 5.69E-02 1.00E+00 218055_s_at NM_018268 WDR41
-4.64E-02 9.14E-02 1.00E+00 218051_s_at NM_022908 NT5DC2 4.51E-02 7.06E-02 1.00E+00 210075_at AF151074 2-Mar
-4.56E-02 6.35E-02 1.00E+00 218002_s_at NM_004887 CXCL14 -4.38E-02 5.28E-02 1.00E+00 219592_at NM_024596 MCPH1
4.52E-02 9.84E-02 1.00E+00 206785_s_at NM_002260 KLRC2/1 -4.31E-02 4.12E-02 1.00E+00 205145_s_at NM_002477 MYL5
-4.48E-02 9.45E-02 1.00E+00 204295_at NM_003172 SURF1 -4.23E-02 2.78E-02 1.00E+00 206108_s_at NM_006275 SFRS6
-4.47E-02 2.78E-02 1.00E+00 206108_s_at NM_006275 SFRS6 4.15E-02 6.82E-02 1.00E+00 204550_x_at NM_000561 GSTM1
4.45E-02 3.91E-03 4.65E-01 212854_x_at AB051480 NBPF10 4.14E-02 3.91E-03 4.54E-01 212854_x_at AB051480 NBPF10
-4.37E-02 5.28E-02 1.00E+00 219592_at NM_024596 MCPH1 -4.04E-02 6.35E-02 1.00E+00 218002_s_at NM_004887 CXCL14
4.34E-02 1.10E-01 1.00E+00 201141_at NM_002510 GPNMB -3.98E-02 7.19E-02 1.00E+00 201123_s_at NM_001970 EIF5A
4.32E-02 2.48E-02 1.00E+00 215823_x_at U64661 LOC341315 3.96E-02 7.62E-06 1.13E-02 Smoking at 
TOD
4.28E-02 4.33E-02 1.00E+00 221752_at AL041728 SSH1 3.93E-02 2.48E-02 9.94E-01 215823_x_at U64661 LOC341315
Male subjects Male subjects
-5.90E-02 1.59E-04 4.87E-02 201137_s_at NM_002121 HLA-DPB1 7.25E-02 2.42E-10 5.40E-06 Drug use
-5.81E-02 8.14E-02 9.87E-01 218948_at AL136679 QRSL1 6.57E-02 1.79E-09 1.33E-05 Alcohol use
-5.36E-02 2.46E-02 6.09E-01 218055_s_at NM_018268 WDR41 -6.16E-02 3.87E-04 8.24E-02 HSV 1 OD Z-
score
4.73E-02 7.55E-03 3.68E-01 215009_s_at U92014 SEC31A -5.44E-02 2.46E-02 6.04E-01 218055_s_at NM_018268 WDR41
3.97E-02 7.06E-02 9.39E-01 209823_x_at M17955 HLA-DQB1 -4.98E-02 8.14E-02 9.84E-01 218948_at AL136679 QRSL1
3.97E-02 3.96E-03 2.69E-01 220313_at NM_022049 GPR88 4.71E-02 7.55E-03 3.64E-01 215009_s_at U92014 SEC31A
3.90E-02 2.96E-02 6.65E-01 204550_x_at NM_000561 GSTM1 -4.11E-02 1.59E-04 4.68E-02 201137_s_at NM_002121 HLA-DPB1
3.64E-02 6.72E-02 9.24E-01 214877_at BE794663 CDKAL1 4.03E-02 4.45E-04 8.62E-02 Smoking at 
TOD
-3.63E-02 9.60E-05 3.77E-02 203851_at NM_002178 IGFBP6 3.97E-02 3.96E-03 2.64E-01 220313_at NM_022049 GPR88
-3.59E-02 8.41E-02 9.94E-01 221875_x_at AW514210 HLA-F 3.67E-02 5.43E-02 8.51E-01 203554_x_at NM_004219 PTTG1
3.58E-02 2.52E-02 6.15E-01 201141_at NM_002510 GPNMB -3.43E-02 8.71E-03 3.84E-01 204670_x_at NM_002125 HLA-DRB1
-3.58E-02 1.57E-02 4.94E-01 203031_s_at NM_000375 UROS -3.35E-02 8.41E-02 9.90E-01 221875_x_at AW514210 HLA-F
-3.56E-02 1.26E-02 4.60E-01 204295_at NM_003172 SURF1 -3.32E-02 1.57E-02 4.90E-01 203031_s_at NM_000375 UROSB
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3.56E-02 5.43E-02 8.55E-01 203554_x_at NM_004219 PTTG1 -3.31E-02 9.60E-05 3.58E-02 203851_at NM_002178 IGFBP6
3.55E-02 4.40E-02 7.84E-01 206339_at NM_004291 CARTPT 3.26E-02 4.40E-02 7.80E-01 206339_at NM_004291 CARTPT
-3.52E-02 9.35E-02 1.00E+00 208729_x_at D83043 HLA-B 3.25E-02 7.06E-02 9.36E-01 209823_x_at M17955 HLA-DQB1
-3.50E-02 8.71E-03 3.88E-01 204670_x_at NM_002125 HLA-DRB1 -3.24E-02 9.35E-02 1.00E+00 208729_x_at D83043 HLA-B
3.48E-02 6.76E-02 9.25E-01 221752_at AL041728 SSH1 3.21E-02 6.76E-02 9.21E-01 221752_at AL041728 SSH1
-3.46E-02 7.98E-02 9.82E-01 203374_s_at AW612376 TPP2 3.16E-02 6.18E-02 8.93E-01 204570_at NM_001864 COX7A1
3.38E-02 6.18E-02 8.97E-01 204570_at NM_001864 COX7A1 3.09E-02 2.96E-02 6.61E-01 204550_x_at NM_000561 GSTM1
Female subjects Female subjects
2.54E-02 1.85E-03 1.00E+00 219044_at NM_018271 THNSL2 3.49E-02 2.07E-02 1.00E+00 Left brain
-2.18E-02 1.71E-02 1.00E+00 208691_at BC001188 TFRC 2.44E-02 1.85E-03 1.00E+00 219044_at NM_018271 THNSL2
-2.12E-02 2.36E-01 1.00E+00 202747_s_at NM_004867 ITM2A -2.08E-02 1.71E-02 1.00E+00 208691_at BC001188 TFRC
-2.04E-02 1.75E-01 1.00E+00 200606_at NM_004415 DSP 2.07E-02 5.93E-04 1.00E+00 Age
-2.03E-02 2.05E-01 1.00E+00 204305_at NM_005932 MIPEP -2.03E-02 2.36E-01 1.00E+00 202747_s_at NM_004867 ITM2A
-2.01E-02 6.29E-02 1.00E+00 207332_s_at NM_003234 TFRC -1.99E-02 1.75E-01 1.00E+00 200606_at NM_004415 DSP
-1.92E-02 5.61E-02 1.00E+00 202746_at AL021786 ITM2A -1.96E-02 2.05E-01 1.00E+00 204305_at NM_005932 MIPEP
-1.86E-02 2.60E-02 1.00E+00 220576_at NM_024989 PGAP1 -1.91E-02 6.29E-02 1.00E+00 207332_s_at NM_003234 TFRC
1.79E-02 1.69E-01 1.00E+00 209619_at K01144 CD74 -1.82E-02 5.61E-02 1.00E+00 202746_at AL021786 ITM2A
1.77E-02 1.23E-01 1.00E+00 220954_s_at NM_013440 PILRB -1.78E-02 2.60E-02 1.00E+00 220576_at NM_024989 PGAP1
-1.75E-02 1.35E-03 1.00E+00 201865_x_at AI432196 NR3C1 1.76E-02 1.23E-01 1.00E+00 220954_s_at NM_013440 PILRB
-1.73E-02 9.17E-02 1.00E+00 209735_at AF098951 ABCG2 1.69E-02 1.69E-01 1.00E+00 209619_at K01144 CD74
-1.71E-02 2.97E-01 1.00E+00 209314_s_at AK024258 HBS1L 1.68E-02 8.54E-02 1.00E+00 Drug use
-1.71E-02 5.99E-02 1.00E+00 209267_s_at AB040120 SLC39A8 -1.66E-02 1.35E-03 1.00E+00 201865_x_at AI432196 NR3C1
-1.70E-02 2.88E-01 1.00E+00 218051_s_at NM_022908 NT5DC2 -1.65E-02 9.17E-02 1.00E+00 209735_at AF098951 ABCG2
-1.66E-02 1.83E-01 1.00E+00 213791_at NM_006211 PENK -1.62E-02 5.99E-02 1.00E+00 209267_s_at AB040120 SLC39A8
-1.66E-02 1.75E-01 1.00E+00 203697_at U91903 FRZB -1.61E-02 1.75E-01 1.00E+00 203697_at U91903 FRZB
-1.63E-02 9.02E-02 1.00E+00 202688_at NM_003810 TNFSF10 -1.61E-02 2.88E-01 1.00E+00 218051_s_at NM_022908 NT5DC2
-1.62E-02 2.61E-01 1.00E+00 217757_at NM_000014 A2M -1.55E-02 1.83E-01 1.00E+00 213791_at NM_006211 PENK
-1.60E-02 6.61E-03 1.00E+00 211671_s_at U01351 NR3C1 -1.55E-02 3.39E-01 1.00E+00 222274_at AW975050 FLJ31568
Table 4: Genes sorted by SVM weight, schizophrenia versus control (Continued)B
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Table 5: Genes sorted by SVM weight, bipolar versus control
Expression data only Demographic, clinical, and expression data
All subjects All subjects
SVM-weight p-value q-value ID GenBank Symbol SVM-weight p-value q-value ID GenBank Symbol
-1.04E-01 4.47E-03 9.53E-02 205033_s_at NM_004084 DEFA1/3 2.00E-01 2.92E-18 4.66E-14 Drug use
-1.03E-01 1.78E-03 6.98E-02 218055_s_at NM_018268 WDR41 1.68E-01 7.09E-13 5.66E-09 Alcohol use
-9.48E-02 1.34E-02 1.46E-01 203231_s_at AW235612 ATXN1 -9.09E-02 3.22E-04 3.62E-02 202203_s_at NM_001144 AMFR
-9.06E-02 1.70E-02 1.63E-01 219525_at NM_018242 SLC47A1 -8.38E-02 4.47E-03 9.46E-02 205033_s_at NM_004084 DEFA1/3
8.92E-02 9.79E-03 1.27E-01 215147_at AF007147 CUGBP2 -7.98E-02 1.34E-02 1.45E-01 203231_s_at AW235612 ATXN1
-8.86E-02 3.22E-04 3.72E-02 202203_s_at NM_001144 AMFR 7.67E-02 6.28E-05 1.96E-02 PMI
7.65E-02 2.36E-02 1.90E-01 204285_s_at AI857639 PMAIP1 7.63E-02 9.79E-03 1.27E-01 215147_at AF007147 CUGBP2
-7.61E-02 1.44E-03 6.36E-02 203031_s_at NM_000375 UROS 6.58E-02 2.36E-02 1.89E-01 204285_s_at AI857639 PMAIP1
-7.44E-02 6.61E-03 1.09E-01 218951_s_at NM_018390 PLCXD1 -6.40E-02 1.78E-03 6.88E-02 218055_s_at NM_018268 WDR41
7.17E-02 6.47E-03 1.09E-01 215528_at AL049390 MGAT5 -6.23E-02 1.70E-02 1.62E-01 219525_at NM_018242 SLC47A1
-6.98E-02 1.54E-03 6.46E-02 221579_s_at AF062530 NUDT3 -5.94E-02 1.05E-02 1.32E-01 209189_at BC004490 FOS
-6.67E-02 1.37E-09 2.19E-05 213921_at NM_001048 SST 5.60E-02 6.47E-03 1.08E-01 215528_at AL049390 MGAT5
-6.62E-02 1.05E-02 1.33E-01 209189_at BC004490 FOS -5.49E-02 6.61E-03 1.08E-01 218951_s_at NM_018390 PLCXD1
-6.48E-02 6.72E-06 9.04E-03 221011_s_at NM_030915 LBH -5.46E-02 1.37E-09 7.31E-06 213921_at NM_001048 SST
6.46E-02 4.79E-03 9.73E-02 217617_at AW451711 PBX1 -5.44E-02 2.53E-03 7.69E-02 203528_at NM_006378 SEMA4D
-5.98E-02 4.63E-03 9.59E-02 204507_s_at NM_000945 PPP3R1 -5.40E-02 1.54E-03 6.37E-02 221579_s_at AF062530 NUDT3
-5.87E-02 1.26E-03 6.14E-02 204545_at NM_000287 PEX6 -5.33E-02 2.49E-03 7.69E-02 200976_s_at NM_006024 TAX1BP1
5.80E-02 2.72E-02 2.02E-01 217482_at AK021987 HEMBB100035
4
5.33E-02 4.79E-03 9.66E-02 217617_at AW451711 PBX1
-5.67E-02 2.53E-03 7.78E-02 203528_at NM_006378 SEMA4D -5.23E-02 1.26E-03 6.05E-02 204545_at NM_000287 PEX6
5.45E-02 1.45E-02 1.52E-01 217055_x_at S83374 SLC1A2 5.17E-02 1.45E-02 1.52E-01 217055_x_at S83374 SLC1A2
Male subjects Male subjects
-8.15E-02 2.96E-05 1.08E-01 219525_at NM_018242 SLC47A1 1.61E-01 4.55E-10 3.34E-06 Alcohol use
-6.62E-02 2.50E-03 3.49E-01 208151_x_at NM_030881 DDX17 1.27E-01 1.68E-12 2.47E-08 Drug use
-6.36E-02 1.02E-02 3.49E-01 218055_s_at NM_018268 WDR41 7.30E-02 3.77E-03 3.48E-01 PMI
-6.35E-02 2.91E-03 3.49E-01 205048_s_at NM_003832 PSPH -6.30E-02 2.96E-05 7.68E-02 219525_at NM_018242 SLC47A1
-6.12E-02 2.15E-03 3.49E-01 218948_at AL136679 QRSL1 -5.73E-02 2.91E-03 3.48E-01 205048_s_at NM_003832 PSPH
-5.44E-02 2.09E-03 3.49E-01 202203_s_at NM_001144 AMFR -5.47E-02 3.85E-03 3.48E-01 205924_at BC005035 RAB3B
5.33E-02 4.53E-03 3.49E-01 216006_at AF070620 WIPF2 -5.16E-02 2.50E-03 3.48E-01 208151_x_at NM_030881 DDX17
-5.09E-02 3.85E-03 3.49E-01 205924_at BC005035 RAB3B -5.14E-02 2.09E-03 3.48E-01 202203_s_at NM_001144 AMFR
-4.90E-02 1.17E-02 3.49E-01 208719_s_at U59321 DDX17 -5.12E-02 2.15E-03 3.48E-01 218948_at AL136679 QRSL1
4.79E-02 1.23E-02 3.49E-01 210738_s_at AF011390 SLC4A4 -4.36E-02 1.02E-02 3.48E-01 218055_s_at NM_018268 WDR41
4.79E-02 4.39E-02 3.49E-01 202853_s_at NM_002958 RYK 4.20E-02 4.53E-03 3.48E-01 216006_at AF070620 WIPF2
4.76E-02 2.39E-02 3.49E-01 207181_s_at NM_001227 CASP7 -3.96E-02 2.06E-04 1.68E-01 Brain pH
-4.74E-02 2.04E-02 3.49E-01 204416_x_at NM_001645 APOC1 -3.84E-02 1.17E-02 3.48E-01 208719_s_at U59321 DDX17
4.53E-02 1.52E-03 3.49E-01 204712_at NM_007191 WIF1 3.76E-02 2.06E-02 3.48E-01 214722_at AW516297 NOTCH2NL
-4.51E-02 3.53E-03 3.49E-01 204545_at NM_000287 PEX6 3.75E-02 4.39E-02 3.48E-01 202853_s_at NM_002958 RYKB
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-4.50E-02 6.16E-03 3.49E-01 205033_s_at NM_004084 DEFA1/3 3.74E-02 9.42E-03 3.48E-01 209291_at AW157094 ID4
4.31E-02 2.46E-02 3.49E-01 219255_x_at NM_018725 IL17RB -3.67E-02 2.04E-02 3.48E-01 204416_x_at NM_001645 APOC1
-4.29E-02 8.23E-05 1.34E-01 213921_at NM_001048 SST -3.60E-02 3.53E-03 3.48E-01 204545_at NM_000287 PEX6
4.26E-02 3.48E-02 3.49E-01 218500_at NM_016647 C8orf55 3.56E-02 1.23E-02 3.48E-01 210738_s_at AF011390 SLC4A4
-4.25E-02 5.38E-07 7.90E-03 202688_at NM_003810 TNFSF10 -3.55E-02 6.16E-03 3.48E-01 205033_s_at NM_004084 DEFA1/3
Female subjects Female subjects
6.17E-02 3.51E-02 3.21E-01 211751_at BC005949 PDE4DIP 9.50E-02 3.19E-08 3.84E-04 Drug use
-5.56E-02 3.95E-02 3.21E-01 202688_at NM_003810 TNFSF10 8.85E-02 3.09E-04 3.21E-01 Left brain
-4.20E-02 1.30E-02 3.21E-01 201222_s_at AL527365 RAD23B 5.17E-02 3.51E-02 3.21E-01 211751_at BC005949 PDE4DIP
-4.19E-02 1.89E-02 3.21E-01 211990_at M27487 HLA-DPA1 5.01E-02 6.64E-06 4.00E-02 Age
-4.04E-02 1.00E-02 3.21E-01 202581_at NM_005346 HSPA1B -4.93E-02 3.95E-02 3.21E-01 202688_at NM_003810 TNFSF10
-3.77E-02 5.25E-02 3.21E-01 202203_s_at NM_001144 AMFR 4.09E-02 2.66E-03 3.21E-01 Alcohol use
-3.74E-02 4.26E-02 3.21E-01 217757_at NM_000014 A2M -3.88E-02 1.30E-02 3.21E-01 201222_s_at AL527365 RAD23B
3.72E-02 5.74E-02 3.21E-01 213757_at AA393940 EIF5A -3.71E-02 1.00E-02 3.21E-01 202581_at NM_005346 HSPA1B
-3.70E-02 2.24E-03 3.21E-01 221579_s_at AF062530 NUDT3 -3.50E-02 5.25E-02 3.21E-01 202203_s_at NM_001144 AMFR
-3.62E-02 1.15E-03 3.21E-01 203416_at NM_000560 CD53 3.46E-02 5.74E-02 3.21E-01 213757_at AA393940 EIF5A
-3.49E-02 2.55E-03 3.21E-01 208691_at BC001188 TFRC -3.29E-02 4.26E-02 3.21E-01 217757_at NM_000014 A2M
3.36E-02 2.92E-03 3.21E-01 205990_s_at NM_003392 WNT5A -3.26E-02 1.15E-03 3.21E-01 203416_at NM_000560 CD53
-3.33E-02 2.68E-02 3.21E-01 202291_s_at NM_000900 MGP -3.25E-02 1.89E-02 3.21E-01 211990_at M27487 HLA-DPA1
-3.32E-02 2.63E-03 3.21E-01 200800_s_at NM_005345 HSPA1A/B -2.99E-02 2.68E-02 3.21E-01 202291_s_at NM_000900 MGP
-3.30E-02 2.60E-02 3.21E-01 211038_s_at BC006312 CROCCL1 -2.95E-02 2.24E-03 3.21E-01 221579_s_at AF062530 NUDT3
-3.27E-02 4.16E-02 3.21E-01 218589_at NM_005767 P2RY5 -2.91E-02 2.63E-03 3.21E-01 200800_s_at NM_005345 HSPA1A/B
-3.23E-02 6.22E-02 3.21E-01 203231_s_at AW235612 ATXN1 2.89E-02 2.92E-03 3.21E-01 205990_s_at NM_003392 WNT5A
-3.21E-02 5.41E-02 3.21E-01 218055_s_at NM_018268 WDR41 -2.89E-02 1.45E-02 3.21E-01 202746_at AL021786 ITM2A
-3.17E-02 3.12E-02 3.21E-01 210004_at AF035776 OLR1 -2.79E-02 5.14E-02 3.21E-01 209458_x_at AF105974 HBA1/2
-3.11E-02 1.70E-02 3.21E-01 206577_at NM_003381 VIP -2.75E-02 6.56E-02 3.21E-01 201718_s_at BF511685 EPB41L2
Table 5: Genes sorted by SVM weight, bipolar versus control (Continued)BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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these results however, post-stratification proved ineffec-
tive because it significantly reduced the amount of data,
and therefore also the power of the statistical methods,
resulting in unacceptably high false discovery rates. We
briefly quantify this in the following paragraph.
Consider the p-value ranking for the schizophrenia versus
control task, expression data only, all subjects (Table 2).
Reporting all top 20 features as being significant results in
a false discovery rate of 3.8%, that is, fewer than one fea-
ture is a false discovery. However, if we compute a similar
ranking on the stratified data, which contains only 121 of
the 332 samples in the original data , then reporting only
the four top-ranked features as significant already yields a
false discovery rate of 62.8%, that is, more than two of
these four may be false discoveries. Because of this high
false discovery rate, we decided not to use stratification in
the paper and to accept the possibility of AU/DU associ-
ated genes in the rankings. Further analysis, possibly using
more data, is required to identify such genes.
Biological network representing the schizophrenia p-value ranking Figure 15
Biological network representing the schizophrenia p-value ranking. The network was generated using Ingenuity Sys-
tems Pathway analysis. The darker the red the more significant the correlation with the disease.BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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Note that this problem is partially mitigated by use of the
SVM-based ranking instead, when using demographic fea-
tures in addition to gene expression. If a gene's correlation
with disease is only because of its correlations with AU/
DU, then the SVM will prefer to place most/all of the
weight on AU and DU rather than on this gene. The gene
will receive high weight only if it provides additional pre-
dictive ability for disease beyond its association with AU/
DU. As a result, the ranking will mostly include genes that
are truly associated to the disease, which may explain the
difference between the SVM and p-value rankings. The
extent of this mitigation requires further study to quantify,
which is difficult because we do not have a ground truth
to compare to, that is, it would require that we know
which genes are directly associated with AU/DU and are
not associated with the diseases.
Conclusion
This paper demonstrates that both bipolar disorder and
schizophrenia induce substantial changes in gene expres-
sion within the brain – substantial enough that each can
be distinguished from normal control with an area under
the ROC curve of over 0.9. The paper also demonstrates
the utility of combining gene expression and clinical data.
Biological network representing the bipolar disorder p-value ranking Figure 16
Biological network representing the bipolar disorder p-value ranking. The network was generated using Ingenuity 
Systems Pathway analysis. The darker the red the more significant the correlation with the disease.BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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To our knowledge, this is the first time such a combina-
tion has been employed on this scale. Finally, the paper
demonstrates the significant advantage of support vector
machines for this task over other widely used algorithms
from statistical classification and machine learning.
Using these classification schemes we have shown an
overlap with the current literature when ranking the genes
according to p-value. In fact, nearly the entire schizophre-
nia and the entire bipolar disorder list are either indicated
in the literature or are involved in a biological network
with a previously implicated gene. However, when rank-
ing the genes based on SVM weight only 1 or 2 genes out
of 20 on each list overlapped with the current literature.
This does not necessarily imply that these methods are not
viable but rather that these may be previously unidenti-
fied candidates that have risen to the top due to the large
sample size of this analysis and the application of alterna-
tive classification algorithms for microarray data analysis.
This paper also discussed the possible impact of variables
such as alcohol and drug use on the presented gene rank-
ings. Post-stratification can correct for such variables, but
it significantly reduces the power of the statistical meth-
ods. Therefore, data for more controls with high values for
these variables is required so that the AU/DU distribu-
tions in the different classes become more similar. It
should also be kept in mind that this is a retrospective
study on a given data set and that all results will require
further clinical validation. Samples in the collection were
matched during the collection process for as many param-
eters as possible. While there may be some confounding
effects from pre-mortem consumption of alcohol and
other non-prescription medication, this analysis is our
best attempt to account for differences in the factors
through analytical means (Torrey, Webster, et al 2000).
Since, these samples are not derived from controlled ani-
mals models we will have to rely on these analytical
means to aid our efforts in dissecting the root causes of
complex diseases.
Methods
Encoding of nominal features
Because most classification techniques that we consider
are restricted to numerical features only, we re-encode
each nominal feature as a numeric feature. Table 1 indi-
cates the encoding after each feature value. For the binary
features "Sex", "Left brain", "Brain region", and "Smoking
at time of death", we use an encoding with three values: 1,
0, and -1, with 0 indicating "unknown". The features that
have essentially ordered values, such as "Alcohol use",
"Drug use" and "Rate of death", we encode with a simple
integer encoding.
Software packages and versions
We choose the SVM-light software version 6.01 [57] for
constructing linear soft margin SVMs. We use the NSC
software PAM version 1.28, which is available at: http://
www-stat.stanford.edu/~tibs/PAM/. We use the reimple-
mentation of C4.5 that is available in the Weka data min-
ing tool version 3.4.4 [58]. We also use Weka 3.4.4's
implementations of NB and kNN. We use the EOV soft-
ware version 1.0 by Hardin et al. [9]. To compute the q-
values, we use the software QVALUE version 1.1 devel-
oped by Storey [15]. All are freely available.
ROC curves and AUC
Most classifiers provide confidence scores for their predic-
tions. The classification behavior of such classifiers can be
modified by applying a threshold to this score: only pre-
dict positive if the confidence is above the given thresh-
old. By varying the threshold, we obtain different ROC
points, which can be connected into a curve. (The curve
can then be used, for example, to select an appropriate
threshold.) We present such a curve for each classifier and
report the corresponding AUC.
To obtain the ROC curves, we use 10-fold cross-validation
(CV). 10-fold CV is often used to evaluate the predictive
performance of classifiers if the number of instances is
small. In this situation, 10-fold CV results in a lower-vari-
ance estimate of error than does the use of a single held-
aside test set. 10-fold CV consists of three steps: (a) parti-
tion the data set D into 10 subsets Ti; (b) train 10 classifi-
ers on the training sets D-Ti; (c) test classifier i on test set
Ti. We pool the predicted confidence values of the classifi-
ers over the 10 test sets to construct the ROC curve. The CV
algorithm that we employ is stratified, which means that
it ensures that the Ti have identical class distributions, or
as nearly identical as possible.
To assess statistical significance when comparing two clas-
sification techniques by AUC value, we use a two-sided
paired t-test. The paired sample values used in the test are
the AUC values computed for the two techniques on the
10 CV test sets.
Algorithm parameters
Most classification techniques come with a number of
parameters. We set all parameters to their default values,
except for the following. The parameter C of SVM-light,
which controls the contribution of the misclassified
examples, is set to 1.0 (SVM-light is not particularly sensi-
tive to C's value). We enable Laplace smoothing of DT's
confidence values. Following Hardin et al. [9], we set
EOV's number of decision stumps N to 20. We enable
Weka's discretization feature for NB. We run kNN with k =
3 neighbors.BMC Genomics 2008, 9:531 http://www.biomedcentral.com/1471-2164/9/531
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We tune NSC's Δ parameter, which controls the amount
of shrinkage, by means of 10-fold CV, as suggested by Tib-
shirani et al. [7]. Recall that we also create ROC curves by
means of CV. To avoid overfitting the test set, we repeat
the parameter tuning each time we run NSC, that is, for
each ROC CV fold. The tuning selects the value of Δ that
maximizes TP + TN, with TP the true positive rate and TN
the proportion of negative examples that are correctly
classified.
The performance of some classification techniques can be
improved by running a feature selection method prior to
constructing the classifier. We implement feature selec-
tion for SVM, NB, and 3NN. The feature selection works
as follows. We perform a two-sided paired t-test for each
feature comparing its value in the two classes. Then we
rank the features by their t-test's p-value and retain the
10% features that most significantly differ in the two
classes (similar to the p-value ranking discussed before).
We repeat the feature selection for each CV fold and per-
form the t-test on the corresponding training set.
To compute the feature ranking by SVM weight, we nor-
malize each feature by subtracting its mean and dividing
by its standard deviation (in the data set at hand), and run
the SVM algorithm on the transformed data. The rationale
behind this is to avoid favoring features with a small value
range in the ranking. We also enable feature selection to
construct the ranking by SVM weight as discussed before.
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Description of additional data files
￿ FeatureRankingsStratified.{doc, pdf} (Microsoft Word
and PDF format): "Feature rankings on post-stratified
data" in additional files 1 and 2.
Feature rankings similar to Tables 2, 3, 4, 5 computed for
a post-stratified copy of the data set. See Section "Impact
of alcohol and drug use" for more information.
￿ FeatureRankingsDetailed.xls (Microsoft Excel format):
"Feature rankings with additional information" in addi-
tional file 3.
Feature rankings that contain the same information as
Tables 2, 3, 4, 5, but also include additional information,
such as gene title and chromosome location.
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